title: Updates on drug discovery in ovarian cancer.
abstract: Drug discovery in the ovarian cancer arena continues to launch important new clinical trials. Many biologic agents are being studied in phase II and phase III clinical trials for recurrent disease. These agents include compounds that disrupt angiogenesis through a variety of mechanisms. Other oncogenic pathways are also specifically targeted such as PARP, MEK, and topoisomerase inhibitors which are currently being studied in phase III trials. Various cytotoxic agents, as well as therapeutic vaccines, are also under investigation, and continue to demonstrate promising new data. The relevant agents in the treatment of ovarian cancer which have demonstrated positive phase II activity will be discussed.
authors.affiliation: The Division of Gynecologic Oncology, University of Arizona Cancer Center, 500 West Thomas Road, Suite 600, Phoenix, AZ 85013 USA ; Creighton University School of Medicine, St. Joseph's Hospital and Medical Center, A Dignity Health Member, 500 West Thomas Road, Suite 600, Phoenix, AZ 85013 USA.
authors.forename: Steven J
authors.initials: SJ
authors.lastname: Gibson
authors.affiliation: The Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, The Chao Family Comprehensive Cancer Center, University of California, Irvine Medical Center, 101 The City Drive South, Building 56, Room 275, Orange, CA 92868 USA.
authors.forename: Krishnansu S
authors.initials: KS
authors.lastname: Tewari
authors.affiliation: The Division of Gynecologic Oncology, University of Arizona Cancer Center, 500 West Thomas Road, Suite 600, Phoenix, AZ 85013 USA ; Creighton University School of Medicine, St. Joseph's Hospital and Medical Center, A Dignity Health Member, 500 West Thomas Road, Suite 600, Phoenix, AZ 85013 USA.
authors.forename: Bradley J
authors.initials: BJ
authors.lastname: Monk
authors.affiliation: The Division of Gynecologic Oncology, University of Arizona Cancer Center, 500 West Thomas Road, Suite 600, Phoenix, AZ 85013 USA ; Creighton University School of Medicine, St. Joseph's Hospital and Medical Center, A Dignity Health Member, 500 West Thomas Road, Suite 600, Phoenix, AZ 85013 USA.
authors.forename: Dana M
authors.initials: DM
authors.lastname: Chase
keywords: Angiogenesis; Chemotherapy; Clinical trials; Ovarian cancer; Recurrent cancer; Targeted therapy